<div>Video: <a href="https://youtu.be/rTRnbFpbG4Y" target="_blank" rel="noreferrer noopener"><a href="https://youtu.be/rTRnbFpbG4Y" target="_blank" class="" rel="nofollow noopener noreferrer">https://youtu.be/rTRnbFpbG4Y</a></a>
</div>
<div><br />
</div>
<div><br />
</div><iframe media_type="0" media_id="rTRnbFpbG4Y" class="youtube-replace" title="YouTube video player" style="margin-bottom:20px;width:560px;height:315px;" src="//www.youtube.com/embed/rTRnbFpbG4Y/?rel=0" frameborder="0" allowfullscreen="1"></iframe>
<div><br />
</div>
<div><br />
</div>
<div>Millions live with multiple sclerosis. We’re two young researchers hoping to find a better future through a novel therapeutic peptide.
</div>
<div><br />
</div>
<div>We’re Henry Hohm and Rasmus Schuster, two undergraduate medical students from Germany studying in the international English-language MD program at UMF “Victor Babeș” University of Medicine and Pharmacy Timișoara, Romania. Science brought us together. A shared passion for neuroscience—and a strong desire to help people with MS—turned us into research partners.
</div>
<div><br />
</div>
<div>We’re now on the brink of something incredible: a once-in-a-lifetime opportunity to join a cutting-edge preclinical research team at the University of Southern California (USC), under the mentorship of award-winning professor Dr. Julio A. Camarero Palao. This lab will allow us to carry out the project we designed ourselves—something we cannot do in our home country due to missing infrastructure.
</div>
<div><br />
</div>
<div>Our goal? To investigate a novel therapeutic peptide called BPC-157 in an experimental model of progressive multiple sclerosis (MS)—the most aggressive and least treatable form of the disease.
</div>
<div><br />
</div>
<div>Multiple sclerosis affects over 2.8 million people globally. It’s a chronic, often debilitating neurological condition where the immune system attacks the protective sheath of nerve cells. For people with progressive MS, the outlook is especially devastating. No current treatments stop the progression. No known cure exists.
</div>
<div><br />
</div>
<div>But there is hope.
</div>
<div><br />
</div>
<div>BPC-157 is a small peptide derived from the body’s own protective proteins. It has shown promise in healing nerves, reducing inflammation, and protecting blood vessels in early studies—but it has never been tested in a validated model of progressive MS. That’s what we want to do.
</div>
<div><br />
</div>
<div>Our study uses a preclinical model that mimics the slow, degenerative nature of progressive MS. With your support, we’ll test whether BPC-157 can reduce neurological damage and help preserve function. If successful, our work could lay the foundation for a completely new therapeutic avenue for MS—something safe, affordable, and accessible.
</div>
<div><br />
</div>
<div>We’ve secured mentorship, lab access, and project approval at USC. Now, there’s just one barrier: funding.
</div>
<div><br />
</div>
<div>We need to raise $31,000 to cover:
</div>
<div><br />
</div>
<ul>
<li>Specialized lab materials and reagents
</li>
<li>Purchase and care for the experimental mice
</li>
<li>Imaging, histology, and behavioral testing
</li>
<li>Travel and living expenses during our 13-week stay at USC
</li>
<li>Research supervision, publication, and contingency
</li>
</ul>
<div><br />
</div>
<div>We’ve carefully budgeted every cent (see full breakdown in our description). We are pursuing scholarships and scientific foundations—but we can’t do it alone.
</div>
<div><br />
</div>
<div>This is more than a student project. This is our commitment to those living with MS.
</div>
<div><br />
</div>
<div>We’re not pharmaceutical companies. We’re not in this for profit. We’re two driven, idealistic medical students who believe in science, and in the people science should serve.
</div>
<div><br />
</div>
<div>Every dollar brings us closer to uncovering a breakthrough.
</div>
<div><br />
</div>
<div>If you believe in scientific curiosity, in giving young researchers a chance, and in a better future for people with MS—please consider donating.
</div>
<div><br />
</div>
<div>From the bottom of our hearts: thank you.
</div>
<div><br />
</div>
<div>—Henry &amp; Rasmus
</div>

Ramona Weser-Hohm

KONSTANTINOS PANAGIOT RODITIS

Daniel Van veeren

Jad Byn

Anonymous

Sandra Schüssler

Ionela Irimia

Rayyan Wels

Doris Sulea

Olaf Kuhlmann

Raimund Weser

Ufuk Özdemir

Johann Weser

Belinda Virnich

Irimia Iasmina

Jannis Zimmer

Monika Hohm

Paul Groß

Research on a NEW Medication for Multiple Sclerosis

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Research on a NEW Medication for Multiple Sclerosis

Still €5,935 to go. Help us build momentum.